Prostate Cancer SP005

April 11, 2017

Sponsor: Sotio a.s.

Number: SP005

The purpose of this study is to determine whether DCVAC/PCa (a new Active Cellular Immunotherapy medicinal product) added onto Standard of Care Chemotherapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer (advanced).

Who’s eligible:

The patient must have histologically (tissue microscopically examined) or cytologically (fluid cells microscopically examined) confirmed prostate adenocarcinoma. There must be a presence of skeletal, and/or soft-tissue/visceral/nodal metastasis (the development of secondary malignant growths at a distance from a primary site of cancer). There must be maintenance of castrate conditions. Life expectancy of at least six months based on Investigator´s judgment. This must be done at least four weeks after surgery or radiotherapy.

This study is for male patients age 18 and older

Available at: Backus Hospital- Eastern Connecticut Hematology and Oncology.

Cancer Clinical Research Office